Success Metrics

Clinical Success Rate

85.7%

Based on 12 completed trials

Completion Rate

86%(12/14)

Active Trials

3(14%)

Results Posted

33%(4 trials)

Terminated

2(9%)

Phase Distribution

Ph phase_1

23%

Ph not_applicable

Ph phase_2

50%

Ph phase_3

Ph phase_4

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution21 total trials

Phase 1Safety & dosage

5(23.8%)

Phase 2Efficacy & side effects

11(52.4%)

Phase 3Large-scale testing

2(9.5%)

Phase 4Post-market surveillance

1(4.8%)

N/ANon-phased studies

2(9.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

12 of 16 finished

Non-Completion Rate

25.0%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(12)

Terminated(4)

Other(3)

Detailed Status

Completed12

unknown3

Recruiting3

Terminated2

Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 4

Trials by Phase

Phase 15 (23.8%)

Phase 211 (52.4%)

Phase 32 (9.5%)

Phase 41 (4.8%)

N/A2 (9.5%)

Trials by Status

completed1255%

terminated29%

unknown314%

recruiting314%

withdrawn29%

Recent Activity

3 active trials

Showing 5 of 22

recruitingphase_3

Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

NCT07644052

completedphase_1

Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities

NCT05273320

View all 22 trials

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more

NCT07644052Phase 3

Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

Recruiting

NCT01517100Phase 1

The Role of Endocannabinoids in Insulin Production and Action

Completed

NCT04801641Phase 2

A Pilot Trial of Nabilone for the Treatment of Obesity

Terminated

NCT04516057Phase 3

Nabilone for Agitation Blinded Intervention Trial

Recruiting

NCT05273320Phase 1

Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities

Completed

NCT05742698Phase 2

Nabilone for Agitation in Frontotemporal Dementia

Recruiting

NCT05494437Phase 2

Effect of PP-01 on Cannabis Withdrawal Syndrome

Completed

NCT04880278Phase 1

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

Withdrawn

NCT03422861Not Applicable

Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients

Unknown

NCT03251326Phase 1

Nabilone in Cannabis Users With PTSD

Terminated

NCT04807829Phase 2

Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

Withdrawn

NCT02911324Phase 1

Cannabinoid Medication for Adults With OCD

Completed

NCT02351882Phase 2

Safety and Efficacy of Nabilone in Alzheimer's Disease

Completed

NCT03210766

Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain

Completed

NCT01347762Phase 2

Nabilone for Cannabis Dependence: A Pilot Study

Completed

NCT02802540Phase 2

Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients

Unknown

NCT02115529Phase 2

Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet

Completed

NCT00480181Phase 4

Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis

Completed

NCT00272207Phase 2

A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia

Completed

NCT00699634Phase 2

Nabilone for the Treatment of Phantom Limb Pain

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 22